+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Chugai Pharmaceutical Co Ltd (4519) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 74 Pages
  • June 2024
  • GlobalData
  • ID: 1291949
Chugai Pharmaceutical Co Ltd (4519) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Chugai Pharmaceutical Co Ltd (Chugai) a subsidiary of F. Hoffmann-La Roche Ltd, specializes in biotechnological research and drug manufacturing. The company manufactures, markets, exports and imports pharmaceutical products in Japan and other countries. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. The company is operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Chuo-ku, Tokyo, Japan.

Chugai Pharmaceutical Co Ltd Key Recent Developments

  • Jun 11, 2024: Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System - Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company
  • May 08, 2024: Chugai, NCCH, OMPU and MICIN Start Company-Sponsored Phase I Study in Oncology with a New Decentralized Clinical Trial Structure - Improving access to the clinical trial for patients far from the institution :
  • Apr 24, 2024: Chugai Pharmaceutical Announces Consolidated Financial Statements for the First Quarter of the Fiscal Year 2024
  • Feb 02, 2024: Chugai Pharmaceutical Announces Consolidated Financial Results for the Fiscal Year 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Chugai Pharmaceutical Co Ltd - Key Facts
  • Chugai Pharmaceutical Co Ltd - Key Employees
  • Chugai Pharmaceutical Co Ltd - Key Employee Biographies
  • Chugai Pharmaceutical Co Ltd - Major Products and Services
  • Chugai Pharmaceutical Co Ltd - History
  • Chugai Pharmaceutical Co Ltd - Company Statement
  • Chugai Pharmaceutical Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Chugai Pharmaceutical Co Ltd - Business Description
  • Other Break-up: Pharmaceutical Sales
  • Performance
  • Other Break-up: Royalties and Other Operating Income
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Overseas
  • Performance
  • R&D Overview
  • Chugai Pharmaceutical Co Ltd - Corporate Strategy
  • Chugai Pharmaceutical Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Chugai Pharmaceutical Co Ltd - Strengths
  • Chugai Pharmaceutical Co Ltd - Weaknesses
  • Chugai Pharmaceutical Co Ltd - Opportunities
  • Chugai Pharmaceutical Co Ltd - Threats
  • Chugai Pharmaceutical Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Chugai Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 11, 2024: Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System - Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company
  • May 08, 2024: Chugai, NCCH, OMPU and MICIN Start Company-Sponsored Phase I Study in Oncology with a New Decentralized Clinical Trial Structure - Improving access to the clinical trial for patients far from the institution -
  • Apr 24, 2024: Chugai Pharmaceutical Announces Consolidated Financial Statements for the First Quarter of the Fiscal Year 2024
  • Feb 02, 2024: Chugai Pharmaceutical Announces Consolidated Financial Results for the Fiscal Year 2023
  • Feb 01, 2024: Chugai Pharmaceutical Announces Personnel and Organizational Changes
  • Oct 24, 2023: Chugai Pharma Announces Consolidated Financial Statements for the Third Quarter of the Fiscal Year 2023
  • Aug 22, 2023: Chugai Pharmaceutical - Personnel changes
  • Jul 27, 2023: Chugai Announces 2023 Half Year Results
  • Jul 14, 2023: Chugai, OMRON, and OMRON SINIC X Begin Testing of Flexible and Highly Human-Friendly Lab Automation System at Chugai Life Science Park Yokohama
  • Jun 27, 2023: Chugai Establishes Corporate Venture Capital to Accelerate Innovation Opportunities with Drug Discovery Start-ups
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Chugai Pharmaceutical Co Ltd, Key Facts
  • Chugai Pharmaceutical Co Ltd, Key Employees
  • Chugai Pharmaceutical Co Ltd, Key Employee Biographies
  • Chugai Pharmaceutical Co Ltd, Major Products and Services
  • Chugai Pharmaceutical Co Ltd, History
  • Chugai Pharmaceutical Co Ltd, Subsidiaries
  • Chugai Pharmaceutical Co Ltd, Key Competitors
  • Chugai Pharmaceutical Co Ltd, Ratios based on current share price
  • Chugai Pharmaceutical Co Ltd, Annual Ratios
  • Chugai Pharmaceutical Co Ltd, Interim Ratios
  • Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Chugai Pharmaceutical Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Chugai Pharmaceutical Co Ltd, Performance Chart (2019 - 2023)
  • Chugai Pharmaceutical Co Ltd, Ratio Charts
  • Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Shionogi & Co Ltd
  • Sumitomo Pharma Co Ltd
  • Kyowa Kirin Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Daiichi Sankyo Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Rohto Pharmaceutical Co Ltd
  • Astellas Pharma Inc